New drugs for peripheral joint psoriatic arthritis
Drug and Therapeutics Bulletin, ISSN: 0012-6543, Vol: 44, Issue: 1, Page: 1-5
2006
- 1Citations
- 53Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Up to 3% of people have psoriasis, and as many as 42% of these have an associated chronic inflammatory arthritis. In up to 20% of such patients, the arthritis progresses to become severe, destructive and deforming. Traditional drug treatments include NSAIDs and disease-modifying anti-rheumatic drugs (DMARDs) used for rheumatoid arthritis. ▼Leflunomide(Arava-Sanofi-Aventis), ▼etanercept(Enbrel-Wyeth) ▼inifliximab (Remicade-Schering-Plough) and ▼adalimumab (Humira-Abbott) are licensed for the treatment of patients with peripheral joint disease in psoriatic arthritis. Here we review drug therapy for such patients, concentrating on the newer agents.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=30944454123&origin=inward; http://dx.doi.org/10.1136/dtb.2006.4411; http://www.ncbi.nlm.nih.gov/pubmed/16425898; https://dtb.bmj.com/lookup/doi/10.1136/dtb.2006.4411; https://dx.doi.org/10.1136/dtb.2006.4411; https://dtb.bmj.com/content/44/1/1
BMJ
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know